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ABSTRACT 
 
Objective:  The objective of this selective EBM review is to determine whether or not hylan 
injections are more effective in reducing stiffness in primary knee osteoarthritis compared to 
hyaluronic acid derivative injections. 
Study Design:  Review of three published, English language randomized controlled trials 
published in 2007, 2008 and 2011. 
Date Sources: Three randomized control trials were found using PubMed.  These studies 
compared the efficacy and safety of hylan injections and hyaluronic acid derivative injections for 
reducing stiffness in primary knee osteoarthritis. 
Outcome(s) Measured:  The efficacy and tolerability of hylan injections for the treatment of 
stiffness in patients with knee osteoarthritis.  The clinical outcome was measured using the 
Western Ontario McMaster University Osteoarthritis Index (WOMAC).   The incidence of 
serious adverse events including septic arthritis, anaphylactic shock, pain, effusion, erythema and 
injection site hematoma.  Adverse events were patient reported with investigator documentation. 
Results:  Juni (2007)8 found that patients given hylan injections compared to hyaluronic acid 
derivative injections showed equal efficacy in improving clinical performance in reducing the 
WOMAC subscores including the stiffness subscore.  Raman (2008)9 found improvement in the 
WOMAC stiffness subscale for both hylan and hyaluronic acid derivative injections, but no 
statistical difference observed between the two injections.  Pavelka (2011)10 found both 
preparations equally effective in reducing the WOMAC stiffness subscale with no significant 
difference between the hylan and hyaluronic acid derivative injection treatment groups. 
Conclusions:  Results from the three randomized controlled studies demonstrate that both hylan 
and hyaluronic acid derivative injections show equal efficacy in reducing stiffness in primary 
knee osteoarthritis.   
Keywords: Knee osteoarthritis, hylan, hyaluronic acid. 
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INTRODUCTION 
Osteoarthritis is a progressive degenerative joint disease that affects joint cartilage and 
bone leading to joint pain and stiffness.  Osteoarthritis is the most common form of arthritis and 
frequently occurs in the hand joints, spine, hips, knees and great toes.1 The diagnosis of 
osteoarthritis is becoming more prevalent as more people are living longer and the population 
obesity rates continue to increase.  As there is no proven treatment to reverse osteoarthritis, the 
goal has become to relieve symptoms and improve function as conservatively as possible.1  
Osteoarthritis is one of the most prominent causes of disability in the United States.1 
Knee osteoarthritis is typically managed by primary care practioners including physician 
assistants in combination with orthopedic surgeons.  In 2010, osteoarthritis accounted for 21.7 
million of all arthritis-related ambulatory medical visits.2  Patients diagnosed with osteoarthritis 
have a higher risk of death compared to the general population.3 Osteoarthritis of the knee affects 
approximately 13% of women and 10% of men aged 60 years and older.3 Knee and hip joint 
replacements accounts for 35% of total arthritis-related procedures during hospitalization.2 
According to the CDC, the rate of total knee replacements have increased 217% from 1992 to 
2011.2 Total knee replacement estimated costs due to hospital expenditures totaled 
approximately 28.5 billion in 2009.2  
While the underlying etiology of knee osteoarthritis is unknown, research has shown that 
osteoarthritis results from local inflammation, genetics, cellular and biochemical processes.4 Risk 
factors for osteoarthritis include advanced age, obesity, occupation, previous injury and a 
positive family history.4 Osteoarthritis of the knee is a progressive chronic disease with clinical 
manifestations including joint pain, swelling, instability and stiffness.  Osteoarthritic pain is 
described as a constant dull and aching pain that increases with impact and relieved by rest.4 
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Patients describe their pain as being worse as the day progresses.  Limited range of motion and 
stiffness may be due to osteophyte formation in the knee and capsular thickening.  Osteoarthritis 
of the knee is diagnosed clinically but can be confirmed with radiographic imaging displaying 
joint space narrowing, osteophytes, and subchondral sclerosis.4  
The goal of treatment for patients with knee osteoarthritis is to reduce pain and improve 
function which can be achieved with nonpharmacological treatment, pharmacologic treatment or 
surgically.  Typical nonpharmacologic treatment include physical therapy, aquatic therapy, 
physical activity, weight management, and the use of assisted devices.1 Initial pharmacologic 
treatment includes acetaminophen, COX-2 inhibitors, nonsteroidal anti-inflammatories, capsaicin 
cream, and diclofenac gels.1 Intraarticular joint injections of glucocorticoid as well as 
viscosupplementation injections such as hylan and hyaluronic acid are recommended after failing 
primary treatment options. Hylan and hyaluronic acid injections have been proposed for 
treatment of osteoarthritis based on the restoration of lubrication from the injection.5 Total joint 
replacement, the most invasive treatment option is reserved for severe knee osteoarthritis.  
Hyaluronic acid naturally occurs in the synovial fluid around the knee joint and absorbs shock.5 
Patients with osteoarthritis have a decreased amount of hyaluronic acid found in their joints.5 
Viscosupplementation augments hyaluronic acid to the joint in efforts to increase lubrication and 
decrease joint pain and stiffness. This paper evaluates three randomized controlled studies 
comparing the safety and efficacy of hylan and hyaluronic acid derivative injections for reducing 
stiffness in patients with primary knee osteoarthritis.   
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not hylan 
injections are more effective in reducing stiffness in primary knee osteoarthritis compared to 
hyaluronic acid derivative injections. 
METHODS 
 This review consists of three randomized controlled trials which were selected based on 
relevance and patient oriented evidence that matters (POEMS).  Although each of the trials had 
specific criteria, the mutual criteria for the studies included men and non-pregnant females with 
radiologically confirmed knee osteoarthritis aged 18 or older.  All studies included intra-articular 
hylan injections once weekly for three consecutive weeks as the intervention therapy.  The 
intervention therapy was compared to intra-articular hyaluronic acid injections.  The outcomes 
measured were the efficacy and tolerability of hylan injections for the treatment of stiffness in 
patients with knee osteoarthritis.  The incidence of serious adverse events included septic 
arthritis, anaphylactic shock, pain, effusion, erythema and injection site hematoma.   
 Key words include knee osteoarthritis, hylan, hyaluronic acid were used to generate the 
articles.  Once these articles were generated, only randomized control trials published after 2006 
were used and selected based on the relevance and the importance of outcome to the patient.  The 
articles chosen were published in English and published in peer-reviewed journals.  The 
performed searches included the use of PubMed database.  Inclusion criteria included 
randomized controlled trial prospective studies and included patients who were 18 years and 
older with primary knee osteoarthritis.  Exclusion criteria included patients who received 
previous intra-articular treatment with corticosteroids, local anesthetic agents or 
viscosupplementation agents in the past 3 months to the study.  Statistics used in this review and 
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calculated by the author using dichotomous data included relative risk increase (RRI), absolute 
risk increase (ARI), numbers needed to harm (NNH) and p-values.  Table 1 displays the 
characteristics of the included studies. 
Table 1: Demographics & Characteristics of included studies 
Study Type # Pts Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Juni8 
(2007) 
Patient 
blind 
RCT 
660 63.3 
± 
12.3 
Men and non-
pregnant women 
with 
radiographically 
confirmed knee 
osteoarthritis with 
symptoms for at 
least 6 months and 
reported pain on 
most days for the 
previous 3 months; 
Did not respond to 
acetaminophen or 
nonsteroidal anti-
inflammatory drugs  
Inflammatory joint disease; 
Previous 
viscosupplementation 
treatment within 6 months; 
Previous replacement 
surgery in the affected 
knee; Chondrocalcinosis 
with evidence from 
radiographs or synovial 
fluid analysis; Infection in 
or around affected knee or 
relevant skin disease 
surrounding injection site 
 
8 A high 
molecular 
weight cross-
linked hylan 
derived from 
rooster combs 
(Synvisc; 
Genzyme, 
Cambridge, MA) 
Administered as 
a series of 3 
weekly 
injections 
Raman9 
(2008) 
Double 
blind 
RCT 
392 42-82 Minimum pain score 
of 6 on a visual 
analogue scale (0-
10, 10 as worst pain) 
in the study knee; 
Patients with 
primary 
osteoarthritis of the 
study knee affecting 
the tibio-femoral +/- 
the patello-femoral 
compartment 
 
Previous surgery to study 
knee; Previous intra-
articular treatment with 
corticosteroids, local 
anesthetic agents or 
viscosupplementation 
agents to the study knee;  
Bilateral knee osteoarthritis 
which warranted treatment 
 
32 Hylan G-F 20 
with average 
molecular 
weight of 6 
million Daltons 
administered as 
a series of 3 
weekly 
injections 
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OUTCOMES MEASURED 
 All studies measured the efficacy outcome of improvement of stiffness using the Western 
Ontario McMaster University Index (WOMAC) stiffness subscale.  In the study by Juni (2007)8, 
the WOMAC stiffness subscale was measured at baseline and 6 months post injection.  In the 
study by Raman (2008)9, the WOMAC stiffness subscale was measured at 3, 6 and 12 months 
following treatment.  In the study by Pavelka (2011)10, the WOMAC stiffness subscale was 
measured at baseline and 26 weeks post treatment.  The safety outcome was measured by self-
reported adverse events at each follow up visit with investigator documentation of adverse events 
including septic arthritis, anaphylactic shock, pain, effusion, erythema and injection site 
hematoma.  Safety outcomes were also assessed using patient-administered questionnaires. 
RESULTS 
 This review assesses three randomized controlled trials to evaluate the efficacy of intra-
articular hylan injections in reducing stiffness in primary knee osteoarthritis compared to 
hyaluronic acid derivative intra-articular injections.  In the study by Juni8, 660 patients with 
symptomatic knee osteoarthritis were enrolled in the study.  Patients were randomly dived into 
three groups by a computer-generated program: first group of 222 patients were treated using 
intra-articular hylan injections; the second group of 219 patients were treated using intra-articular 
Pavelka10 Double 
blind 
RCT 
381 40-81 Radiologically 
confirmed diagnosis 
of osteoarthritis of 
the affected and 
clinically diagnosed 
by an American 
Colleague of 
Rheumatology  
 
Body Mass Index ≥32 
kg/m^2; 
Viscosupplementation to 
knee within the past year or 
initiation of physical 
therapy in the past 3 
months;  
 
27 Once weekly for 
3 weeks 
16mg/2ml 
(0.8%) of intra-
articular hylan A 
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avian hyaluronic acid injections and the third group of 219 patients were treated using intra-
articular bacterial hyaluronic acid injections (third group will not be discussed in this review). 
The patients in each group received one cycle of three intra-articular injections of 2ml per knee 
treated at weekly intervals.  All injections were performed per the Swiss Association of 
Rheumatologists guidelines.    Data were collected at baseline and 6 months after the last intra-
articular injection was performed.  At baseline, all three groups had similar clinical 
characteristics with no statistical differences regarding the WOMAC stiffness subscale.   
WOMAC scores were analyzed using analysis of covariance adjusted for baseline values.  The 
results determined that there was a 0.1 (95% CI -0.3, 0.4) change for the WOMAC stiffness 
score from baseline between the hylan and hyaluronic acid derivative injections.   
Local adverse events including effusion and flare were obtained during the first 6 months 
of the study.  During the first 6 months of the study, 9.5% of patients receiving the hylan 
injection experienced local adverse events and 7.3% of patients receiving the hyaluronic acid 
injection experienced local adverse events with a difference of 2.2% (95% Cl 2.4, 6.7).  The 
trend toward an increase in local adverse events in the hylan receiving group increased in the 
second cycle resulting in a difference of 6.4% (95% Cl 0.6, 12.2).  During the first 6 months of 
the study, 15 of 222 patients receiving hylan and 25 of 438 patients receiving hyaluronic acid 
experienced serious adverse events.  Serious adverse events are characterized as neoplasms, 
endocrine and metabolic disorders, mental and behavior disorders, disorders of the nervous 
system, disorders of the circulatory system, disorders of connective tissues, disorder of 
genitourinary system, septic arthritis and anaphylactic shock (which only occurred after injection 
of hylan).  To measure safety of hylan and hyaluronic acid derivative, the NNH was calculated 
and resulted as -76. 
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Table 3: Safety and adverse events (calculated data for treatment using dichotomous data) 
CER 
(Proportion 
of patients 
having 
adverse 
events with 
hylan) 
EER 
(Proportion 
of patients 
having 
adverse 
events with 
hyaluronic 
acid 
derivative) 
Relative risk 
increase 
(RRI) 
Absolute 
risk 
increase 
(ARI) 
Numbers 
needed to 
harm (NNH) 
95% CI 
 
6.8% 
 
 5.5% 
 
-19.1% 
 
-1.3% 
 
-76 
 
 
-2.4, 6.7 
 
In the prospective randomized study completed by Raman9, 392 patients who met criteria 
of having primary knee osteoarthritis participated in this study.  There were no substantial 
differences in the age or sex between the two groups.  There were 199 patients who received 
hylan intra-articular injections and 193 patients received hyaluronic acid intra-articular 
injections. All patients were randomly allocated to receive either hylan or hyaluronic acid 
injections by computer generator.  Hylan was administered in a series of 3 weekly injections and 
hyaluronic acid was administered in a series of 5 weekly injections per the manufacturer’s 
recommendations.  All injections were performed by the same surgeon using a default blind 
technique.  Patients were informed to be 24 hours analgesia free before baseline measurement 
and were told to avoid non-steroidal anti-inflammatories for 6 months.  Data were collected 
using the WOMAC stiffness subscale at 3 months, 6 months and 12 months post treatment.  
There was improvement in the WOMAC stiffness subscale at 3,6 and 12 months post treatment 
and no statistical difference observed between the two groups at any follow up visit. 
Figure 1: WOMAC improvement at 6 months 
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 Safety and adverse events were evaluated at each patient visit throughout the study.  
There were 39 patients who reported treatment related adverse events in the hylan injection 
group while 30 patients reported adverse events in the hyaluronate group.  There was 1 severe 
adverse event reported within the hylan group in which the patient was admitted to the hospital 
and diagnosed with “pseudo-sepsis” in the knee.  All other reports were characterized as minor 
adverse events which mostly included injection site pain.  32 of the patient reported adverse 
events in the hylan group occurred within 48 hours of the injection.  Of note, there were no 
systemic adverse events reported in either the hylan or hyaluronic acid injection groups.  To 
measure safety of hylan and hyaluronic acid derivative, the NNH was calculated and resulted as -
25.   
Table 5: Safety and adverse events (calculated data for treatment using dichotomous data) 
CER 
 
EER 
 
Relative risk 
increase 
(RRI) 
Absolute risk 
increase 
(ARI) 
Numbers needed 
to harm (NNH) 
 
20% 
 
 16% 
 
-20% 
 
-4% 
 
-25 
 
 
 In the double-blind randomized controlled trial by Pavelka10, 381 patients who were 
diagnosed with primary knee osteoarthritis and aged between 40 and 81 years.  189 patients 
Figure 1: Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F 
20 and sodium hyaluronate in the treatment of osteoarthritis of the knee -- a prospective 
randomized clinical trial. 
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received hylan 16 mg/2 ml intra-articular injections while 192 patients received hyaluronic acid 
derivative 16 mg/2ml intra-articular injections.  Patients were randomized to receive once 
weekly injections in a three-week interval for both groups.  Patients were given a one month 
supply of rescue medication however patients were informed to not consume this within 24 hours 
prior to study visits.  Use of rescue medications and adverse events were recorded in a patient 
journal.  The WOMAC stiffness subscale was measured at baseline and 26 weeks post treatment.  
At baseline, there were no statistical differences between the groups.  The results determined that 
the WOMAC stiffness score from baseline to 26 weeks did not differ significantly between 
treatment groups. 
Table 6:  WOMAC stiffness score at baseline and 26 month follow up 
 Baseline 26 month follow up 
 Hylan Hyaluronic Acid Hylan Hyaluronic Acid 
WOMAC stiffness score 50.1 ± 19.1 50.1 ± 19.4 25.8   25.7   
 
 Adverse reactions were assessed and reported throughout the 26 weeks.  Adverse 
reactions were characterized as injection site hematoma, injection site pain, arthralgia and joint 
swelling.  5 adverse events were reported within the hylan injection group and 1 adverse event 
was reported within the hyaluronic acid injection group.  There was a total of 7 severe adverse 
events reported: 6 events reported in the hylan injection group and 1 event reported in the 
hyaluronic acid group.  To measure safety of hylan and hyaluronic acid derivative, the NNH was 
calculated and resulted as -41.  
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Table 7: Safety and adverse events (calculated data for treatment using dichotomous data) 
 
CER 
 
EER 
 
Relative risk 
increase 
(RRI) 
Absolute risk 
increase 
(ARI) 
Numbers needed 
to harm (NNH) 
 
2.9% 
 
 0.54% 
 
-82.8% 
 
-2.4% 
 
-41 
 
 
DISCUSSION 
 This systematic review of three randomized controlled trials evaluated the efficacy of 
hylan compared to hyaluronic acid derivatives regarding improving stiffness in patients with 
knee osteoarthritis.  Unfortunately, there is not a cure for osteoarthritis or the process of a 
degenerating joint.  While viscosupplementation will not cure osteoarthritis, it has been used as a 
therapeutic modality of knee osteoarthritis for several years.  Viscosupplements including hylan 
and hyaluronic acid derivative injections have been approved by the FDA for the treatment of 
primary knee osteoarthritis.  Viscosupplements are available in the United States however the 
wholesale price is approximately $1,500 per knee for a treatment series.6 Most insurance 
companies require failing conservative treatment options such as analgesics, physical therapy 
and possibly receiving an intra-articular glucocorticoid injection before approving 
viscosupplementation treatments.   
 There were notable limitations within the three randomized control trial studies.  The first 
limitation included the lack of a placebo control in all three trials.  While all three trials used the 
same hylan injection (Synvisc), there were three different hyaluronic acid derivative injections 
used.  In the study by Juni8, a non-cross linked medium molecular weight hyaluronic acid 
derivative known as Orthovisc was used.  In the study by Raman9, Hyalgan was used as the 
hyaluronate viscous solution.  A chemically non-modified sodium hyaluronate known as 
Hood, Hylan and Hyaluronic Acid Injections 11 
 
Sinovial was used in the study by Pavelka10.  Secondly, the studies by Juni8 and Pavelka10 
involved different physicians performing the viscosupplementation injections which can be 
considered a limitation due to the variety of injection techniques.  Viscosupplementation 
injections require a precise technique to work effectively and limit adverse side effects.7  
In the study by Raman9, the hyaluronic acid derivative injection required 5 injections 
compared to the 3 injections required with the hylan creating a treatment bias.  However, the 
manufacturer of the hyaluronic acid injection recommended to follow their guidelines.  Finally, 
stiffness was assessed during the 6 month and 12 month follow up visits in the studies by Juni8 
and Raman9.  Extending the follow up time would allow for a better understanding of efficacy 
and the hylan injection’s full effects in regards to improving stiffness.   
CONCLUSION 
  Based on this systemic review of the three randomized controlled studies, hylan 
injections do not prove to be more effective in reducing stiffness in primary knee osteoarthritis 
compared to hyaluronic acid derivative injections.  The WOMAC stiffness score used in all three 
studies was assessed via questionnaire format.  Future studies may benefit from an objective 
form of measuring stiffness such as range of motion measurements performed at follow up visits.   
The actual effectiveness of hylan or hyaluronic acid derivatives reducing stiffness in primary 
knee osteoarthritis could not be proved in any three trials due to the lack of a placebo control 
group.  Although both viscosupplements were statistically equivalent in reducing stiffness, data 
from all three studies displayed an increase number in local and severe adverse events within the 
hylan injection groups.  Future studies are warranted to evaluate the length of the effects of the 
viscosupplements and how often injections series are recommended for patients with primary 
knee osteoarthritis.
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